Literature DB >> 10348343

The double-stranded RNA activated protein kinase PKR physically associates with the tumor suppressor p53 protein and phosphorylates human p53 on serine 392 in vitro.

A R Cuddihy1, A H Wong, N W Tam, S Li, A E Koromilas.   

Abstract

The tumor suppressor p53 is a multifunctional protein that plays a critical role in modulating cellular responses upon DNA damage or other stresses. These functions of p53 are regulated both by protein-protein interactions and phosphorylation. The double-stranded RNA activated protein kinase PKR is a serine/threonine kinase that modulates protein synthesis through the phosphorylation of translation initiation factor eIF-2alpha. PKR is an interferon (IFN)-inducible protein that is thought to mediate the anti-viral and anti-proliferative effects of IFN via its capacity to inhibit protein synthesis. Here we report that PKR physically associates with p53. The interaction of PKR with p53 is enhanced by IFNs and upon conditions that p53 acquires a wild type conformation. PKR/p53 complex formation in vitro requires the N-terminal regulatory domain of PKR and the last 30 amino acids of the C-terminus of human p53. In addition, p53 may function as a substrate of PKR since phosphorylation of human p53 on serine392 is induced by activated PKR in vitro. These novel findings raise the possibility of a functional interaction between PKR and p53 in vivo, which may account, at least in part, for the ability of each protein to regulate gene expression at both the transcriptional and the translational levels.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10348343     DOI: 10.1038/sj.onc.1202620

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  55 in total

Review 1.  Double-stranded RNA-activated protein kinase mediates virus-induced apoptosis: a new role for an old actor.

Authors:  R J Kaufman
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-12       Impact factor: 11.205

2.  Modular structure of PACT: distinct domains for binding and activating PKR.

Authors:  G A Peters; R Hartmann; J Qin; G C Sen
Journal:  Mol Cell Biol       Date:  2001-03       Impact factor: 4.272

Review 3.  Dial 9-1-1 for p53: mechanisms of p53 activation by cellular stress.

Authors:  M Ljungman
Journal:  Neoplasia       Date:  2000 May-Jun       Impact factor: 5.715

4.  Role for p53 in gene induction by double-stranded RNA.

Authors:  B T Hummer; X L Li; B A Hassel
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

5.  Inhibition of PACT-mediated activation of PKR by the herpes simplex virus type 1 Us11 protein.

Authors:  Gregory A Peters; David Khoo; Ian Mohr; Ganes C Sen
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

6.  Curaxins: anticancer compounds that simultaneously suppress NF-κB and activate p53 by targeting FACT.

Authors:  Alexander V Gasparian; Catherine A Burkhart; Andrei A Purmal; Leonid Brodsky; Mahadeb Pal; Madhi Saranadasa; Dmitry A Bosykh; Mairead Commane; Olga A Guryanova; Srabani Pal; Alfiya Safina; Sergey Sviridov; Igor E Koman; Jean Veith; Anton A Komar; Andrei V Gudkov; Katerina V Gurova
Journal:  Sci Transl Med       Date:  2011-08-10       Impact factor: 17.956

7.  Vesicular stomatitis virus expressing tumor suppressor p53 is a highly attenuated, potent oncolytic agent.

Authors:  Joshua F Heiber; Glen N Barber
Journal:  J Virol       Date:  2011-08-03       Impact factor: 5.103

8.  Hepatitis C virus envelope protein E2 does not inhibit PKR by simple competition with autophosphorylation sites in the RNA-binding domain.

Authors:  D R Taylor; B Tian; P R Romano; A G Hinnebusch; M M Lai; M B Mathews
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

9.  Down-regulation of p53 by double-stranded RNA modulates the antiviral response.

Authors:  Joao T Marques; Dominique Rebouillat; Chilakamarti V Ramana; Junko Murakami; Jason E Hill; Andrei Gudkov; Robert H Silverman; George R Stark; Bryan R G Williams
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

10.  Role of PKR and Type I IFNs in viral control during primary and secondary infection.

Authors:  Yumi Nakayama; Erin H Plisch; Jeremy Sullivan; Chester Thomas; Charles J Czuprynski; Bryan R G Williams; M Suresh
Journal:  PLoS Pathog       Date:  2010-06-24       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.